Epidemiology, Diagnostics, and Treatment of Narcolepsy in Germany: The DORMIO Study
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives: This study aimed to investigate the prevalence, incidence, and real-world diagnostic and treatment patterns, healthcare resource utilization (HCRU), and associated costs of narcolepsy in Germany. Methods: This study was based on German claims data (2013–2018). Any patient with at least two outpatient specialist diagnoses and/or one inpatient diagnosis of narcolepsy was eligible for inclusion. Three cohorts were specified: 1) narcolepsy-prevalent patients alive on July 1, 2017; 2) narcolepsy-incident patients; and 3) newly treated patients. Descriptive analyses of the outcome measures were conducted. Results: We identified 133 prevalent narcolepsy patients (mean age: 46.2 years, 36.3% female), 71 incident patients, and 41 treatment starters. The prevalence of narcolepsy was 3.1–9.1 per 100,000 persons within the German population; the cumulative incidence between July 1, 2017, and June 30, 2018, was 0.83/100,000 persons. Among the incident patients, 62.0% underwent at least one predefined diagnostic procedure. Modafinil was the most prescribed medication for the treatment starters (46.3%) and prevalent patients (24.1%), but 59.4% of the prevalent patients did not receive any narcolepsy-specific pharmacological treatment. Prevalent patients with narcolepsy consulted physicians significantly more often than a healthy matched control group and experienced more all-cause hospitalizations. The mean total direct healthcare costs were higher for narcolepsy patients by €2,429 per patient-year. Conclusions: Not all narcolepsy patients undergo appropriate diagnostic procedures or narcolepsy-specific medications, as indicated by the treatment guidelines. More emphasis on the optimization of the management of this disease is needed, given its high prevalence and associated economic burden.
Abstract
Objectives: This study aimed to investigate the prevalence, incidence, and real-world diagnostic and treatment patterns, healthcare resource utilization (HCRU), and associated costs of narcolepsy in Germany. Methods: This study was based on German claims data (2013–2018). Any patient with at least two outpatient specialist diagnoses and/or one inpatient diagnosis of narcolepsy was eligible for inclusion. Three cohorts were specified: 1) narcolepsy-prevalent patients alive on July 1, 2017; 2) narcolepsy-incident patients; and 3) newly treated patients. Descriptive analyses of the outcome measures were conducted. Results: We identified 133 prevalent narcolepsy patients (mean age: 46.2 years, 36.3% female), 71 incident patients, and 41 treatment starters. The prevalence of narcolepsy was 3.1–9.1 per 100,000 persons within the German population; the cumulative incidence between July 1, 2017, and June 30, 2018, was 0.83/100,000 persons. Among the incident patients, 62.0% underwent at least one predefined diagnostic procedure. Modafinil was the most prescribed medication for the treatment starters (46.3%) and prevalent patients (24.1%), but 59.4% of the prevalent patients did not receive any narcolepsy-specific pharmacological treatment. Prevalent patients with narcolepsy consulted physicians significantly more often than a healthy matched control group and experienced more all-cause hospitalizations. The mean total direct healthcare costs were higher for narcolepsy patients by €2,429 per patient-year. Conclusions: Not all narcolepsy patients undergo appropriate diagnostic procedures or narcolepsy-specific medications, as indicated by the treatment guidelines. More emphasis on the optimization of the management of this disease is needed, given its high prevalence and associated economic burden.
참고문헌 (45)
- Lucie Barateau, "Recent advances in treatment for narcolepsy", Therapeutic Advances in Neurological Disorders, 12, pp.175628641987562~ (2019), SAGE Publications[DOI]
- Mahoney CE, "The neurobiological basis of narcolepsy", Nat Rev Neurosci, 20, pp.83~93 (2019)[DOI]
- G. Mayer, "Narkolepsie", Der Nervenarzt, 85(1), pp.26~34 (2014), Springer Science and Business Media LLC[DOI]
- Lois E. Krahn, "Characterizing the Emotions That Trigger Cataplexy", The Journal of Neuropsychiatry and Clinical Neurosciences, 17(1), pp.45~50 (2005), American Psychiatric Association Publishing[DOI]
- Thorpy M, "Sleep disorders medicine", pp.475~484 (2017), Springer
- Mayer G, "The implications of gender and age at onset of first symptoms in narcoleptic patients in Germany—results from retrospective evaluation of hospital records", Somnologie, 6(1), pp.13~18 (2002), Springer Science and Business Media LLC[DOI]
- Natalia M. Flores, "The Humanistic and Economic Burden of Narcolepsy", Journal of Clinical Sleep Medicine, 12(03), pp.401~407 (2016), American Academy of Sleep Medicine (AASM)[DOI]
- Sophie Bayard, "Executive Control of Attention in Narcolepsy", PLoS ONE, 7(4), pp.e33525~ (2012), Public Library of Science (PLoS)[DOI]
- Fabio Pizza, "Car Crashes and Central Disorders of Hypersomnolence: A French Study", PLOS ONE, 10(6), pp.e0129386~ (2015), Public Library of Science (PLoS)[DOI]
- FRANCESCA INGRAVALLO, "Medico-legal assessment of disability in narcolepsy: an interobserver reliability study", Journal of Sleep Research, 17(1), pp.111~119 (2008), Wiley[DOI]
- Alexander Cohen, "Comorbidities in a community sample of narcolepsy", Sleep Medicine, 43, pp.14~18 (2018), Elsevier BV[DOI]
- Morse AM, "Narcolepsy and psychiatric disorders: comorbidities or shared pathophysiology?", Med Sci (Basel), 6, pp.16~ (2018)[DOI]
- Yves Dauvilliers, "Non-Dipping Blood Pressure Profile in Narcolepsy with Cataplexy", PLoS ONE, 7(6), pp.e38977~ (2012), Public Library of Science (PLoS)[DOI]
- Birgit Frauscher, "Delayed Diagnosis, Range of Severity, and Multiple Sleep Comorbidities: A Clinical and Polysomnographic Analysis of 100 Patients of the Innsbruck Narcolepsy Cohort", Journal of Clinical Sleep Medicine, 09(08), pp.805~812 (2013), American Academy of Sleep Medicine (AASM)[DOI]
- Marín Agudelo HA, "Cognitive behavioral treatment for narcolepsy: can it complement pharmacotherapy?", Sleep Sci, 7, pp.30~42 (2014)[DOI]
- Koziorynska EI, "Narcolepsy : clinical approach to etiology, diagnosis, and treatment", Rev Neurol Dis, 8, pp.e97~e106 (2011)
- Gerloff C, "Leitlinien für Diagnostik und therapie in der neurologie" (2012), Thieme
- Ulf Kallweit, "Pharmacological management of narcolepsy with and without cataplexy", Expert Opinion on Pharmacotherapy, 18(8), pp.809~817 (2017), Informa UK Limited[DOI]
- Michael J. Thorpy, "Clinical and practical considerations in the pharmacologic management of narcolepsy", Sleep Medicine, 16(1), pp.9~18 (2015), Elsevier BV[DOI]
- Mary Charlson, "Validation of a combined comorbidity index", Journal of Clinical Epidemiology, 47(11), pp.1245~1251 (1994), Elsevier BV[DOI]
- Vijaya Sundararajan, "New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality", Journal of Clinical Epidemiology, 57(12), pp.1288~1294 (2004), Elsevier BV[DOI]
- Doris Oberle, "Incidence of Narcolepsy in Germany", Sleep, 38(10), pp.1619~1628 (2015), Oxford University Press (OUP)[DOI]
- W.T. Longstreth, "Prevalence of narcolepsy in King County, Washington, USA", Sleep Medicine, 10(4), pp.422~426 (2009), Elsevier BV[DOI]
- Michael H. Silber, "The Epidemiology of Narcolepsy in Olmsted County, Minnesota: A Population-Based Study", Sleep, 25(2), pp.197~202 (2002), Oxford University Press (OUP)[DOI]
- Darren Scheer, "Prevalence and incidence of narcolepsy in a US health care claims database, 2008–2010", Sleep, 42(7) (2019), Oxford University Press (OUP)[DOI]
- Shin YK, "Prevalence of narcolepsy-cataplexy in Korean adolescents", Acta Neurol Scand, 117, pp.273~278 (2008)[DOI]
- Yun-Kwok Wing, "The prevalence of narcolepsy among Chinese in Hong Kong", Annals of Neurology, 51(5), pp.578~584 (2002), Wiley[DOI]
- Christer Hublin, "The prevalence of narcolepsy: An epidemiological study of the Finnish Twin Cohort", Annals of Neurology, 35(6), pp.709~716 (1994), Wiley[DOI]
- M. M. Ohayon, "Prevalence of narcolepsy symptomatology and diagnosis in the European general population", Neurology, 58(12), pp.1826~1833 (2002), Ovid Technologies (Wolters Kluwer Health)[DOI]
- Ester Tió, "The prevalence of narcolepsy in Catalunya (Spain)", Journal of Sleep Research, 27(5), pp.e12640~ (2018), Wiley[DOI]
- Michael J. Thorpy, "Delayed diagnosis of narcolepsy: characterization and impact", Sleep Medicine, 15(5), pp.502~507 (2014), Elsevier BV[DOI]
- Emma Morrish, "Factors associated with a delay in the diagnosis of narcolepsy", Sleep Medicine, 5(1), pp.37~41 (2004), Elsevier BV[DOI]
- Julie Flygare, "Narcolepsy: Let the Patient's Voice Awaken Us!", The American Journal of Medicine, 128(1), pp.10~13 (2015), Elsevier BV[DOI]
- Russell Rosenberg, "The role of home sleep testing for evaluation of patients with excessive daytime sleepiness: focus on obstructive sleep apnea and narcolepsy", Sleep Medicine, 56, pp.80~89 (2019), Elsevier BV[DOI]
- J. Black, "Medical comorbidity in narcolepsy: findings from the Burden of Narcolepsy Disease (BOND) study", Sleep Medicine, 33, pp.13~18 (2017), Elsevier BV[DOI]
- Min-Jing Lee, "Comorbidity of narcolepsy and depressive disorders: a nationwide population-based study in Taiwan", Sleep Medicine, 39, pp.95~100 (2017), Elsevier BV[DOI]
- Poul Jennum, "Comorbidity and Mortality of Narcolepsy: A Controlled Retro- and Prospective National Study", Sleep, 36(6), pp.835~840 (2013), Oxford University Press (OUP)[DOI]
- Giuseppe Plazzi, "Restless Legs Syndrome is Frequent in Narcolepsy with Cataplexy Patients", Sleep, 33(5), pp.689~694 (2010), Oxford University Press (OUP)[DOI]
- Merrill M. Mitler, "Narcolepsy", Journal of Clinical Neurophysiology, 7(1), pp.93~118 (1990), Ovid Technologies (Wolters Kluwer Health)[DOI]
- Wise MS, "Objective measures of sleepiness and wakefulness: application to the real world?", J Clin Neurophysiol, 23, pp.39~49 (2006)[DOI]
- Jennum P, "The economic consequences of narcolepsy", J Clin Sleep Med, 5, pp.240~245 (2009)
- Poul Jennum, "Health, social, and economic consequences of narcolepsy: A controlled national study evaluating the societal effect on patients and their partners", Sleep Medicine, 13(8), pp.1086~1093 (2012), Elsevier BV[DOI]
- Ginger Carls, "Burden of disease in pediatric narcolepsy: a claims-based analysis of health care utilization, costs, and comorbidities", Sleep Medicine, 66, pp.110~118 (2020), Elsevier BV[DOI]
- Jed Black, "The Burden of Narcolepsy Disease (BOND) study: health-care utilization and cost findings", Sleep Medicine, 15(5), pp.522~529 (2014), Elsevier BV[DOI]
- Richard Dodel, "The Socioeconomic Impact of Narcolepsy", Sleep, 27(6), pp.1123~1128 (2004), Oxford University Press (OUP)[DOI]